ATG12

Across TCGA pan-cancer cohorts, ATG12 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ATG12’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where ATG12 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ATG12 is over-expressed in tumor.

PDAC, LUAD, and HNSC are the cancer types where ATG12 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATG12 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	II,III,IV	+1.129	<.001	8	view →
LUAD	Female	All	+0.353	<.001	5	view →
HNSC	All	IV	+0.237	.013	2	view →
CCRCC	Male	III,IV	+0.114	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ATG12–PDAC

Open the PDAC breakdown →